JP2008535819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535819A5 JP2008535819A5 JP2008503191A JP2008503191A JP2008535819A5 JP 2008535819 A5 JP2008535819 A5 JP 2008535819A5 JP 2008503191 A JP2008503191 A JP 2008503191A JP 2008503191 A JP2008503191 A JP 2008503191A JP 2008535819 A5 JP2008535819 A5 JP 2008535819A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- vegf trap
- protein
- sucrose
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66512505P | 2005-03-25 | 2005-03-25 | |
| US60/665,125 | 2005-03-25 | ||
| PCT/US2006/010600 WO2006104852A2 (en) | 2005-03-25 | 2006-03-22 | Vegf antagonist formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012282406A Division JP5752671B2 (ja) | 2005-03-25 | 2012-12-26 | Ｖｅｇｆアンタゴニスト製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008535819A JP2008535819A (ja) | 2008-09-04 |
| JP2008535819A5 true JP2008535819A5 (enExample) | 2013-02-21 |
| JP5376573B2 JP5376573B2 (ja) | 2013-12-25 |
Family
ID=36678320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503191A Expired - Lifetime JP5376573B2 (ja) | 2005-03-25 | 2006-03-22 | Ｖｅｇｆアンタゴニスト製剤 |
| JP2012282406A Expired - Lifetime JP5752671B2 (ja) | 2005-03-25 | 2012-12-26 | Ｖｅｇｆアンタゴニスト製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012282406A Expired - Lifetime JP5752671B2 (ja) | 2005-03-25 | 2012-12-26 | Ｖｅｇｆアンタゴニスト製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (16) | US20060217311A1 (enExample) |
| EP (3) | EP1861116B1 (enExample) |
| JP (2) | JP5376573B2 (enExample) |
| KR (1) | KR101327270B1 (enExample) |
| CN (2) | CN101141975B (enExample) |
| AU (1) | AU2006229930C1 (enExample) |
| CA (3) | CA3142945A1 (enExample) |
| CY (2) | CY1116980T1 (enExample) |
| DK (2) | DK2586459T3 (enExample) |
| ES (2) | ES2633574T3 (enExample) |
| HU (2) | HUE034109T2 (enExample) |
| IL (2) | IL185606A (enExample) |
| LT (1) | LT2586459T (enExample) |
| NZ (1) | NZ560713A (enExample) |
| PL (2) | PL2586459T3 (enExample) |
| PT (2) | PT1861116E (enExample) |
| SI (2) | SI2586459T1 (enExample) |
| WO (1) | WO2006104852A2 (enExample) |
| ZA (1) | ZA200708845B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| US7572893B2 (en) * | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| AU2012202859C1 (en) * | 2006-06-16 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| CA2703263C (en) | 2007-11-01 | 2014-03-18 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
| NZ592591A (en) * | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| CN102552875B (zh) * | 2010-12-09 | 2015-05-20 | 上海国健生物技术研究院 | 一种双功能vegf受体融合蛋白制剂 |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| CA2833144C (en) * | 2011-04-14 | 2020-09-29 | The Regents Of The University Of California | Multilayer thin film drug delivery device and methods of making and using the same |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| AU2012340107B2 (en) | 2011-11-18 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Polymer protein microparticles |
| KR102063028B1 (ko) | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| US9801362B2 (en) * | 2012-03-16 | 2017-10-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
| HK1206628A1 (en) * | 2012-08-02 | 2016-01-15 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CN103110105A (zh) * | 2012-11-14 | 2013-05-22 | 江苏江山制药有限公司 | 食品添加剂无糖维生素c钠盐颗粒的生产方法 |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| RS58957B1 (sr) | 2014-07-18 | 2019-08-30 | Sanofi Sa | Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka |
| CN104940926B (zh) | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
| WO2016120753A1 (en) | 2015-01-28 | 2016-08-04 | Pfizer Inc. | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| KR20210157427A (ko) | 2015-12-03 | 2021-12-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| EP3407868A1 (en) | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| CN110022855B (zh) | 2016-10-07 | 2024-07-16 | 瑞泽恩制药公司 | 室温稳定的冻干蛋白质 |
| CN109937034B (zh) * | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
| USD849856S1 (en) | 2017-06-28 | 2019-05-28 | Jumpsport, Inc. | Standing platform |
| US11273205B2 (en) * | 2017-07-25 | 2022-03-15 | Jiangsu Hengrui Medicine Co., Ltd. | IL-15 protein complex pharmaceutical composition |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| WO2019099921A2 (en) | 2017-11-17 | 2019-05-23 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| MY202872A (en) | 2017-11-20 | 2024-05-28 | Just Evotec Biologics Inc | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| KR20200093621A (ko) | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| EP3730126B1 (en) * | 2017-12-22 | 2025-05-14 | Samsung Bioepis Co., Ltd. | Liquid composition comprising vegf antagonist |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2019173767A1 (en) | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
| IL309560B2 (en) | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| KR102337471B1 (ko) * | 2019-12-23 | 2021-12-09 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형 |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| EP4190310A4 (en) * | 2020-07-31 | 2024-01-17 | Celltrion, Inc. | Stable pharmaceutical preparation |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| CN118043350A (zh) * | 2021-08-13 | 2024-05-14 | 信达生物制药(苏州)有限公司 | 抗vegf a和vegf c双特异性抗体及其用途 |
| CN120204358A (zh) * | 2023-12-27 | 2025-06-27 | 成都康弘生物科技有限公司 | 一种含有抗vegf的融合蛋白的药物组合物 |
| US12240888B1 (en) | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
| WO2025227916A1 (zh) | 2024-04-29 | 2025-11-06 | 齐鲁制药有限公司 | 包含阿柏西普和其变体的组合物以及相关方法和应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| WO1993022336A1 (en) * | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) * | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| JPH10273450A (ja) | 1997-03-27 | 1998-10-13 | Toagosei Co Ltd | 眼内血管新生性疾患治療薬 |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
| US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| IL145675A0 (en) | 1999-04-16 | 2002-06-30 | Genentech Inc | Vascular endothelial cell growth factor variants and uses thereof |
| EP1179541B1 (en) | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7396664B2 (en) * | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7001892B1 (en) * | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| DE60139944D1 (de) * | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| CA2476934C (en) | 2002-02-27 | 2009-06-16 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| JP4730909B2 (ja) | 2003-03-28 | 2011-07-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆ媒介性活性を遮断することにより糖尿病を処置する方法 |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| US20040266688A1 (en) | 2003-05-14 | 2004-12-30 | Nayak Nihar R | Methods for modulating endometrium |
| AU2004242586C1 (en) | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| CA2519875C (en) | 2003-06-06 | 2014-01-14 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with vegf inhibitors |
| ITMI20031261A1 (it) | 2003-06-20 | 2004-12-21 | Messersi Packaging Srl | Macchina reggiatrice con gruppo perfezionato di movimentazione della reggia. |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| JP2007501239A (ja) | 2003-08-06 | 2007-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 放射線治療と組み合わせたｖｅｇｆアンタゴニストの使用 |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| US7422741B2 (en) | 2004-03-05 | 2008-09-09 | Vegenics Limited | VEGFR-3 fusion proteins |
| WO2005102303A2 (en) | 2004-04-21 | 2005-11-03 | Advanced Ocular Systems Limited | Antiprostaglandins for the treatment of ocular pathologies |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| ES2381014T3 (es) | 2004-06-08 | 2012-05-22 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína quimérica inhibidora de la angiogénesis y el uso |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| EP2583685A1 (en) * | 2004-06-10 | 2013-04-24 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
| EP1755645A2 (en) | 2004-06-18 | 2007-02-28 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
| CN1997386B (zh) | 2004-07-30 | 2012-05-30 | 瑞泽恩制药公司 | 通过阻断vegf介导的活性来治疗i型糖尿病的方法 |
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| EP1877438A2 (en) * | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| CN107115294B (zh) | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| DE202013000688U1 (de) | 2012-07-03 | 2013-03-05 | Novartis Ag | Glas-Spritze |
| JP6071099B1 (ja) | 2014-01-25 | 2017-02-01 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管の新生又は成長を抑制する融合タンパク質及びその用途 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
-
2006
- 2006-03-22 CA CA3142945A patent/CA3142945A1/en active Pending
- 2006-03-22 ZA ZA200708845A patent/ZA200708845B/xx unknown
- 2006-03-22 CA CA2598711A patent/CA2598711C/en not_active Expired - Lifetime
- 2006-03-22 HU HUE13152402A patent/HUE034109T2/en unknown
- 2006-03-22 EP EP06748594.6A patent/EP1861116B1/en not_active Expired - Lifetime
- 2006-03-22 ES ES13152402.7T patent/ES2633574T3/es not_active Expired - Lifetime
- 2006-03-22 PL PL13152402T patent/PL2586459T3/pl unknown
- 2006-03-22 EP EP17159239.7A patent/EP3195874A1/en not_active Ceased
- 2006-03-22 DK DK13152402.7T patent/DK2586459T3/en active
- 2006-03-22 ES ES06748594.6T patent/ES2548238T3/es not_active Expired - Lifetime
- 2006-03-22 CA CA2995971A patent/CA2995971A1/en active Pending
- 2006-03-22 WO PCT/US2006/010600 patent/WO2006104852A2/en not_active Ceased
- 2006-03-22 SI SI200632195T patent/SI2586459T1/sl unknown
- 2006-03-22 PL PL06748594T patent/PL1861116T3/pl unknown
- 2006-03-22 AU AU2006229930A patent/AU2006229930C1/en active Active
- 2006-03-22 LT LTEP13152402.7T patent/LT2586459T/lt unknown
- 2006-03-22 SI SI200631996T patent/SI1861116T1/sl unknown
- 2006-03-22 CN CN2006800085696A patent/CN101141975B/zh not_active Expired - Lifetime
- 2006-03-22 PT PT67485946T patent/PT1861116E/pt unknown
- 2006-03-22 HU HUE06748594A patent/HUE027096T2/en unknown
- 2006-03-22 NZ NZ560713A patent/NZ560713A/en not_active IP Right Cessation
- 2006-03-22 US US11/387,256 patent/US20060217311A1/en not_active Abandoned
- 2006-03-22 CN CN201210090068.4A patent/CN102614134B/zh not_active Expired - Lifetime
- 2006-03-22 PT PT131524027T patent/PT2586459T/pt unknown
- 2006-03-22 KR KR1020077024202A patent/KR101327270B1/ko not_active Expired - Lifetime
- 2006-03-22 EP EP13152402.7A patent/EP2586459B1/en not_active Expired - Lifetime
- 2006-03-22 JP JP2008503191A patent/JP5376573B2/ja not_active Expired - Lifetime
- 2006-03-22 DK DK06748594.6T patent/DK1861116T3/en active
-
2007
- 2007-08-30 IL IL185606A patent/IL185606A/en active IP Right Grant
-
2010
- 2010-07-13 US US12/835,065 patent/US8110546B2/en not_active Expired - Lifetime
-
2012
- 2012-01-04 US US13/343,214 patent/US8404638B2/en not_active Expired - Lifetime
- 2012-03-23 US US13/428,510 patent/US8710004B2/en not_active Expired - Lifetime
- 2012-12-26 JP JP2012282406A patent/JP5752671B2/ja not_active Expired - Lifetime
-
2013
- 2013-06-04 US US13/909,745 patent/US8921316B2/en not_active Expired - Lifetime
- 2013-06-27 IL IL227215A patent/IL227215A/en active IP Right Grant
-
2014
- 2014-11-21 US US14/550,385 patent/US9416167B2/en not_active Expired - Lifetime
-
2015
- 2015-11-26 CY CY20151101068T patent/CY1116980T1/el unknown
-
2016
- 2016-03-08 US US15/064,343 patent/US9511140B2/en not_active Expired - Lifetime
- 2016-05-10 US US15/150,840 patent/US9636400B2/en not_active Expired - Fee Related
- 2016-11-03 US US15/342,989 patent/US20170073407A1/en not_active Abandoned
-
2017
- 2017-08-02 CY CY20171100827T patent/CY1119243T1/el unknown
- 2017-08-31 US US15/692,893 patent/US10406226B2/en not_active Expired - Lifetime
-
2019
- 2019-08-08 US US16/535,610 patent/US10857231B2/en not_active Expired - Lifetime
-
2020
- 2020-11-17 US US16/950,584 patent/US11806398B2/en active Active
-
2021
- 2021-05-04 US US17/307,240 patent/US20210252147A1/en not_active Abandoned
- 2021-05-05 US US17/308,801 patent/US20210252105A1/en not_active Abandoned
- 2021-05-06 US US17/313,627 patent/US20210393778A1/en not_active Abandoned
- 2021-05-07 US US17/314,992 patent/US20210393530A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6050902B2 (ja) | 即効型インスリン組成物 | |
| KR102161177B1 (ko) | 지속형 인슐린분비 펩타이드 결합체 액상 제제 | |
| JP2009524595A5 (enExample) | ||
| CY1124703T1 (el) | Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς | |
| PH12021552788A1 (en) | Stabilized formulations containing anti-angptl3 antibodies | |
| JP2018504420A5 (enExample) | ||
| JP2013127002A5 (enExample) | ||
| ECSP099642A (es) | Formulaciones estables de anticuerpo | |
| US20150157725A1 (en) | Transmucosal delivery of peptides and proteins | |
| CN103402536A (zh) | 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法 | |
| KR20170061140A (ko) | 펩티드 또는 단백질 약물의 경구 전달을 위한 약제학적 제형 | |
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| WO2009032246A3 (en) | Particulate compositions for delivery of poorly soluble drugs | |
| HRP20251316T1 (hr) | Stabilne formulacije polipeptida i njihova upotreba | |
| US9636376B2 (en) | Stable compositions of peptide epoxy ketones | |
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| JP2019512012A5 (enExample) | ||
| WO2015190378A1 (ja) | 安定なアダリムマブ水性製剤 | |
| CN101912600A (zh) | 改善胰岛素在溶液中稳定性的方法 | |
| Tratsiakovich et al. | Myocardial protection by co-administration of L-arginine and tetrahydrobiopterin during ischemia and reperfusion | |
| JP5892940B2 (ja) | クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物 | |
| CN1802171B (zh) | 不包含血清白蛋白的人红细胞生成素的稳定水溶液 | |
| Wu et al. | Development of a KRP-based pH-responsive drug delivery system for solid tumors | |
| JP2003504395A5 (enExample) | ||
| TW201815410A (zh) | 藥物之經黏膜吸收促進劑 |